Impact of Laparotomy and Intraperitoneal Hyperthermic Instillation (LIHI) on the oxaliplatin pharmacokinetics after intravenous administration in Wistar rats

Cancer Chemother Pharmacol. 2017 Mar;79(3):621-627. doi: 10.1007/s00280-017-3244-6. Epub 2017 Feb 6.

Abstract

Purpose: In peritoneal metastasis condition, the fact that most of the disease is limited to the peritoneal cavity laid the foundations for a surgical treatment, including intraperitoneal hyperthermic chemotherapy (HIPEC). The aim of this study was to evaluate the impact of the surgical procedures implied in open HIPEC technique, referred to laparotomy procedures followed by an intraperitoneal hyperthermic instillation (LIHI) on oxaliplatin tissue distribution and elimination. To delimit the influence of this procedure alone, oxaliplatin was administered as an intravenous (iv) bolus in both groups.

Methods: An experimental model in Wistar rats was employed, and LIHI was evaluated as a dichotomous covariate by using a population pharmacokinetic (PK) approach. Rats were randomized in two groups receiving 1.5 mg iv oxaliplatin alone or 1.5 mg iv oxaliplatin under LIHI conditions, carrying out a hyperthermic 5% dextrose instillation. The oxaliplatin plasma concentrations were characterized by an open two-compartment PK model.

Results: Results concluded that surgical conditions affect the oxaliplatin elimination and distribution from blood to peripheral tissues, increasing the systemic drug exposure. Concretely, oxaliplatin peripheral volume of distribution, and clearance decreased by 48.6% and 55.3%, respectively, compared to the control group that resulted in a two-fold increase of the area under the concentration time curve.

Conclusions: Comparison in clinical practice of oxaliplatin PK parameters obtained after iv administrations with those obtained after HIPEC interventions must be done carefully. This would limit the use of iv PK parameters to simulate new scenarios for oxaliplatin in HIPEC.

Keywords: Hyperthermia; Intraperitoneal chemotherapy; Oxaliplatin; Peritoneal metastasis; Population pharmacokinetics.

MeSH terms

  • Administration, Intravenous
  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / pharmacokinetics*
  • Area Under Curve
  • Hyperthermia, Induced*
  • Injections, Intraperitoneal
  • Laparotomy / methods*
  • Male
  • Models, Statistical
  • Organoplatinum Compounds / administration & dosage*
  • Organoplatinum Compounds / pharmacokinetics*
  • Oxaliplatin
  • Peritoneal Neoplasms / drug therapy
  • Rats
  • Rats, Wistar
  • Reproducibility of Results
  • Tissue Distribution

Substances

  • Antineoplastic Agents
  • Organoplatinum Compounds
  • Oxaliplatin